Abstract
Orlistat is a novel, noncentrally acting antiobesity agent that selectively inhibits gastro intestinal lipase activity, there by reducing the absorption of dietary fat by approximately one-third. In a series of 1- and 2-yr randomized, placebo-controlled trials of obese subjects, treatment with orlistat in combination with a mildly calorie-restricted diet consistently produced significantly greater mean weight loss than diet alone. More orlistat-treated subjects than placebo recipients achieved clinically meaningful weight reduction (≥5% or ≥10% of initial body weight) after 1 and 2 yr. Orlistat was also associated with a significant reduction in the regain of lost weight during long-term treatment. In addition, orlistat therapy resulted in significant improvements in several cardiovascular risk factors including serum total and low-density lipoprotein—cholesterol, serum insulin levels, systolic and diastolic blood pressure, and waist circumference. Furthermore, obese subjects with type 2 diabetes achieved a significantly greater decrease in body weight with orlistat compared with placebo, as well as significant improvements in HbA1c and fasting glucose levels. Among subjects with impaired glucose tolerance, orlistat compared with placebo reduced the proportion who developed type 2 diabetes. Conversely, orlistat increased the proportion of subjects who achieved a normalization of glucose tolerance. Orlistat acts locally in the gastrointestinal tract and is only minimally absorbed. In long-term clinical trials, orlistat was well tolerated by both diabetic and nondiabetic subjects.
Similar content being viewed by others
References
Lissner, L. and Heitmann, B. L. (1995). Eur. J. Clin. Nutr. 49, 79–90.
Golay, A. and Bobbioni, E. (1997). Int. J. Obes. 21(Suppl.), S2-S11.
Bray, G. A. and Popkin, B. M. (1998). Am. J. Clin. Nutr. 68, 1157–1173.
Rolls, B. J. (1995). Am. J. Clin. Nutr. 61(Suppl. 4), 960S-967S.
Blundell, J. E., Burley, V. J., Cotton, J. R., and Lawton, C. L. (1993). Am. J. Clin. Nutr. 57(5 Suppl.), 772S-777S.
Drewnowski, A., Kurth, C., Holden-Wiltse, J., and Saari, J. (1992). Appetite 18, 207–221.
Abbott, W., Howard, B., Christin, L., et al. (1988). Am. J. Physiol. 255, E332-E337.
Schutz, Y., Flatt, J. P., and Jequier, E. (1989). Am. J. Clin. Nutr. 50, 307–314.
Tremblay, A., Plourde, G., Despres, J.-P, and Bouchard, C. (1989). Am. J. Clin. Nutr. 49, 799–805.
Thomas, C., Peters, J., Reed, G., Abumrad, N. N., Sun, M., and Hill, J. O. (1992). Am. J. Clin. Nutr. 55, 934–942.
Astrup, A., Buemann, B., Christenson, N., and Toubro, S. (1994). Am. J. Physiol. 266, E592-E599.
Astrup, A., Ryan, L., Storgaard, M., Saris, W. H. M., Hill, J. O. (1999). Int. J. Obes. 23(Suppl. 5), A304.
Hyman, F. N., Sempos, E., Saltsman, J., and Glinsmann, W. H. (1993). Arch. Intern. Med. 119, 681–687.
Wadden, T. A. (1993). Arch. Intern. Med. 119, 688–693.
Guerciolini, R. (1997). Int. J. Obes. 21 (Suppl.), S12-S23.
Zhi, J., Melia, A. T., Guerciolini, R., et al. (1994). Clin. Pharmacol. Ther. 56, 82–85.
Shepherd, T. Y., Jensen, D. R., Blotner, S., Zhi, J., Guerciolini R., Pace, D., and Eckel R. H. (2000). Int. J. Obes., in press.
Davidson, M. H., Hauptman, J., DiGirolamo, M., et al. (1999). JAMA 281, 235–242.
Sjostrom, L., Rissanen, A., Andersen, T., et al. (1998). Lancet 352, 167–172.
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., and Noseda, G. (2000). Obes. Res., in press.
Hauptman, J., Lucas, C., Boldrin, M., and Collins, H. (2000). Arch. Fam. Med., in press.
Hill, J. O., Hauptman, J., Anderson, J. W., et al. (1999). Am. J. Clin. Nutr. 69, 1108–1116.
Hollander, P. A., Elbein, S. C., Hirsch, I. B., et al. (1998). Diabetes Care 21, 1288–1294.
Henry, R. R., Wiest-Kent, T. A., Schaeffer, O. G., Kolterman, O. G., and Olefsky, J. M. (1986). Diabetes 35, 155–164.
Wing, R. R., Marcus, M. D., Epstein, L. H., and Salata, R. (1987). Diabetes Care 10, 563–566.
Guare, J. C., Wing, R. R., and Grant, A. (1995). Obes. Res. 3, 329–335.
United Kingdom Prospective Diabetes Study (UKPDS). (1995). BMJ 310, 83–88.
Hanefield, M., Fischer, S., Schmechel, H., et al. (1991). Diabetes Care 14, 308–317.
Lemieux, S., Prud'homme, D., Bouchard, C., Tremblay, A., and Despres, J. P. (1996). Am. J. Clin. Nutr. 64, 685–693.
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., and Willett, W. C. (1994). Diabetes Care 17, 961–969.
Rimm, E. B., Stampfer, M. J., Giovanucci, E., et al. (1995). Am. J. Epidemiols. 141, 1117–1127.
Rexrode, K. M., Carey, V. J., Hennekans, C. H., et al. (1998). JAMA 280, 1843–1848.
Goldstein, D. J. (1992). Int. J. Obes. 16, 397–415.
Pi-Sunyer, F. X. (1996). Clin Ther. 18, 1006–1035.
Langford, H. G., Davis, B. R., Blaufox, D., et al. (1991). Hypertension 17, 210–217.
Whelton, P. K., Appel, L. J., Espeland, M. A., et al. (1998). JAMA 79, 839–846.
National Institutes of Health. National Heart, Lung and Blood Institute. (1997). The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National Institutes of Health: Bethesda, MD.
Patakay, Z. and Golay, A. (1999). Int. J. Obes. 23(Suppl. 5), S175.
Després, J., Lamarche, B., Mauriege, P., et al. (1996). N. Engl. J. Med. 334, 952–957.
Niskanen, L., Turpeinen, A., Penttila, I., and Uusitupa, M. I. (1998). Diabetes Care 21, 1861–1869.
Balkau, B., Shipley, M., Jarrett, R. J., et al. (1998). Diabetes Care 21, 360–367.
Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M.N., Rissanen, A. Wilding, J. P. H., and Sjöström, L. (2000). Arch. Intern. Med., in press.
Aronne, L. J. (1998). J. Am. Diet. Assoc. 98(Suppl. 2), S23-S26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hauptman, J. Orlistat. Endocr 13, 201–206 (2000). https://doi.org/10.1385/ENDO:13:2:201
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:13:2:201